Bruno Fang

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors

Antoine Italiano, Teresa García Manrique, Enrique Grande Pulido, Katie Kerrigan et autres

fr, es, us, pl (code pays fourni par la source)

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib

Pascale Tomasini, Óscar Juan, Raffaele Califano, Chien‐Chung Lin et autres

fr, es, gb, tw, be, cn, pl, ar, in, my, it, br, mx, ca, il, us (code pays fourni par la source)

Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud et autres

Abstract P4-08-20: Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors

Jennifer Man, Bruno Fang, Alexander Philipovskiy, Brian Andrew Van Tine et autres

Abstract PS8-09: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study

Alberto J. Montero, Kari B. Wisinski, Bruno Fang, Kelly McCann et autres

A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial

Lucia Masárová, Brandi Reeves, Firas El Chaer, Lynda Foltz et autres

us, ca, gb (code pays fourni par la source)

604 Magrolimab + docetaxel in previously treated patients with metastatic non-small cell lung cancer (NSCLC)

Oscar Juan-Vidal, Bruno Fang, Luis Paz‐Ares, Ana Laura Ortega Granados et autres

es, us, fr (code pays fourni par la source)

Supplementary Data 1 from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer

David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud et autres

Data from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer

David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud et autres

Supplementary Data 1 from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer

David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud et autres

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares, Robin Cornelissen et autres

kr, jp, es, nl, fr, us, au, cn (code pays fourni par la source)

Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)

Phillip H. Kuo, Michael J. Morris, Jacob Hesterman, A. Tuba Kendi et autres

us, fr (code pays fourni par la source)